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Abstract  
Limb girdle muscular dystrophy type 2L or anoctaminopathy is a condition mainly 
characterized by adult onset proximal lower limb muscular weakness and raised CK 
values, due to recessive ANO5 gene mutations. An exon 5 founder mutation 
(c.191dupA) has been identified in most of the British and German LGMD2L patients 
so far reported. We aimed to further investigate the prevalence and spectrum of ANO5 
gene mutations and related clinical phenotypes, by screening 205 undiagnosed 
patients referred to our molecular service with a clinical suspicion of 
anoctaminopathy. A total of 42 unrelated patients had two ANO5 mutations (21%), 
while 14 carried a single change. We identified 34 pathogenic changes, 16 135 of 
which are novel. The c.191dupA mutation represents 61% of mutated alleles and 
appears to be less prevalent in non-Northern European populations. Retrospective 
clinical analysis corroborates the prevalently proximal lower limb phenotype, the 
male predominance and absence of major cardiac or respiratory involvement. 
Identification of cases with isolated hyperCKaemia and very late symptomatic male 
and female subjects further confirms the broadensextension of the phenotypic 
spectrum of the disease. Anoctaminopathy appears to be one of the most common 
adult muscular dystrophies in Northern Europe, with a prevalence of about 20-25% in 
unselected undiagnosed cases.  
 
Key words:  
ANO5, LGMD2L, gender, common mutation 
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Introduction 
Limb girdle muscular dystrophy type 2L (LGMD2L) is a condition 
characterized by proximal weakness affecting primarily the pelvic girdle and leg 
muscles, with less prominent distal leg weakness and high CK values (Hicks et al, 
2011). LGMD2L, together with a more distal variant also known as non-dysferlin 
Miyoshi muscular dystrophy type 3 (MMD3) as well as some cases of isolated 
hyperCKaemia and pseudometabolic myopathy, have been shown to be associated 
with recessive mutations in the ANO5 gene (OMIM accession number 608662; 
Bolduc et al, 2010; Hicks et al, 2011; Milone et al, 2012; Deschauer et al, 2012; 
Schessl et al, 2012; Penttilä et al, 2012; Bouquet et al, 2012; Magri et al, 2012; 
Pénisson-Besnier et al, 2012; Wahbi et al, 2012; Witting et al, 2012; Little et al, 
20132; Neusch et al, 2012). The prevalence of ANO5 gene related conditions, or so-
called anoctaminopathies, is not yet fully established, but preliminary data from 
Northern England indicate that LGMD2L is the 3
rd
 most common type of LGMD with 
a minimum prevalence of 0.27/100 000 (Hicks et al, 2011). To date, 35 67 variants 
(35 pathogenic; www.lovd.nl/ANO5) mutations have been detected all over the ANO5 
gene, with one a common mutation (c.191dupA) in exon 5, likely the result of a 
founder effect of Northern European origin (Hicks et al, 2011), and another in exon 
20 (c.2272C>T) more frequent in the Finnish population (Penttilä et al, 2012). Early 
clinical and MRI studies indicated wide clinical heterogeneity and a gender difference 
in expression, with anoctaminopathies appearing to be less frequent and less severe in 
females (Sarkozy et al, 2012).  
In the present study, we investigated the prevalence and spectrum of ANO5 
gene mutations in the so far largest and clinically most heterogeneous cohort of 
Formatted: Font: Times New Roman, Not
Bold, Not Highlight
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patients with anoctaminopathy, in order to better describe the phenotype, gender 
predominance and allelic variability of this emerging disease. 
Materials and Methods 
The study was performed on a total of 205 unrelated individuals of both sexes, 
referred for ANO5 gene analysis to the Newcastle upon Tyne Limb-Girdle Referral 
Centre in view of their phenotypes compatible with anoctaminopathy, ranging from 
isolated hyperCKaemia, myalgia and raised CK, to MMD3 and LGMD2L. Patients 
were referred from different clinical centers, but primarily from the UK, Germany, 
France, Spain, the USA and Belgium. The cohort previously reported by Hicks et al. 
was not included in this study (Hicks et al, 2011). Clinical details for patients with 
ANO5 mutation were collected retrospectively. The clinical suspicion of 
anoctaminopathy was made following clinical examination, muscle assessment and 
clinical investigations including CK analysis, EMG, muscle MRI and/or muscle 
biopsy. Possible alternative diagnoses, such as LGMD2B, LGMD2I and LGMD2A, 
were excluded as appropriate. DNAs of affected and unaffected relatives were 
collected and segregation analysis performed where available. 
DNA extraction and direct sequencing of the ANO5 gene (Gene Bank 
accession number NM_213599.2) was performed as described elsewhere (Hicks et al, 
2011).  Sequence variants were coded reflecting cDNA numbering with +1 
corresponding to the A of the ATG translation initiation codon in the reference 
sequence, according to guidelines (www.hgvs.org/mutnomen). The initiation codon is 
codon 1. Novelty of each sequence variant was checked in the ANO5 locus specific 
database (www.lovd.nl/ANO5). To investigate whether novel missense, synonymous 
or intronic variations not located in splice sites could possibly represent pathogenic 
Formatted: Font: 12 pt, Not Bold, Font
color: Auto, English (U.S.)
Formatted: Font: 12 pt, Not Bold, Font
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sequence variants, we performed in silico analysis using the Alamut mutation analysis 
software (Interactive Biosoftware, v2.1).  
Results 
Genetic analysis 
ANO5 gene sequence variants were identified in 90/205 unrelated individuals 
(46%) and 5 affected relatives (Table 1, Suppl. Table 1). Fifty-one patients were 
found to carry 2 or more ANO5 variants in homozygosity or compound 
heterozygosity, while further 39 patients showed one single ANO5 change (Tables 1 
and 2). A total of 42 ANO5 gene variants were identified, 32 27 of which novel 
(Tables 1 and 2). Twenty variants were missense (47%), 4 frameshift (9%), 6 splice 
site (14%), 2 stop (5%), 1 synonymous (2%) and 10 intronic (24%) (Table 2). The 
pathogenicity of 16 135 novel variants is supported by their predicted effect on 
protein product, by their recurrence in multiple unrelated patients, by segregation in 
affected family members, absence in SNPs databases and in silico analysis. Four 
missense changes, two of which were previously reported in literature as pathogenic 
(c.155A>G and c.2387C>T)), were considered benign variants based on in silico 
analysis and/or their frequency in control population (Table 2) (Wahbi et al, 2012). It 
was not possible to further comment on the pathogenicity of a missense (c.968C>G) 
and a synonymous change (c.2256G>A) as well as 10 intronic variants in absence of 
segregation studies or further cDNA investigations.  
Forty-twoForty-two  unrelated patients (N.1-N.42) carried 2 likely pathogenic 
ANO5 gene changes, 24 19 in homozygosity and 20 283 in compound heterozygosity 
(Table 1). Patients N.21B, N.22B, N.28B, N.40B-C carried the pathogenic variants 
found in their affected relative (i.e. N.21A, N.22A, N.28A and N.40A). In 14 patients 
(N.43-N.56) only one single pathogenic variant was identified. cDNA analysis or 
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genomic dosage analysis was not performed to rule out a possible 2nd deep intronic 
change or deletion/duplication of the part/entire ANO5 gene. Seven novel pathogenic 
variants were recurrent (Tables 1 and 2). The common c.191dupA exon 5 mutation 
was found in homozygosity in 16 patients, in compound heterozygosity with another 
identified mutation in 19, and in heterozygosity without a 2nd detectable mutation in 
further 5 individuals. Geographic origin of patients, indicated in Table 1, confirms 
that the common variant is present also in populations other than the British and 
German populations. Additionally, two already reported (c.692G>T, c.1927dupA) and 
2 novel (c.1898+1G>A, c.2417A>G) mutations were also identified in multiple 
patients, and further 3 novel changes were found in homozygosity in 3 individuals 
(Tables 1 and 2). Parental DNA screening or ANO5 genomic dosage analysis was not 
performed yet for the homozygous patients, and hemizygosity of parts or the entire 
ANO5 locus cannot be ruled out. 
Phenotypic analysis 
Among patients with 2 likely pathogenic changes (total 47 patients, including 
42 unrelated subjects and 5 affected relatives), 39 were male (83%) and 8 were female 
(17%). Clinical information was available for 4144 patients and relatives with 2 
pathogenic changes 44 patients (34 males, and 7 females) (table 3). Thirty-four 
patients (83%) were male and 7 were female (17%). Age at onset ranged between 
teens and late 70s, with an average age at onset of 35 years. At time of genetic 
diagnosis, 3/7 females and 3/374 males were completely asymptomatic or very mildly 
symptomatic. Average CK values were 4000 IU/l, ranging from around 200 IU/l up to 
about 30.000 IU/L. Detailed information about last muscle assessment At time of last 
assessmentwas available for 38/47 individuals., a A predominantly proximal 
involvement was observed in 22/38 (57%) patients, while 4/38 (10%) and 3/38 (8%) 
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patients showed a more distal or proximal plus distal involvement, respectively. No or 
very mild clinical symptoms (myalgia and/or raised CK) were reported in 9 patients 
with 2 ANO5 mutations (25%).  
Symptoms at onset and overall clinical presentation in males were similar to 
what has been previously described for patients with ANO5 gene mutations (Table 3; 
Hicks et al, 2011). Although age at onset was similar on average (34 years), in this 
cohort we observed a wider range, with patients showing first symptoms in their teens 
to patients only symptomatic in late adulthood, with one patient (Pt. N.38) showing 
first symptoms of proximal lower limb weakness and wasting at the age of 77 years 
only. Moreover, the phenotype was extremely mild in 3 individuals, only showing 
raised CK values (Pt. N.15 and N.36) or some mild proximal leg weakness after a 
disease course of 32 years (Pt. N40B). Patient N.21B was diagnosed as part of family 
screening and showed no symptoms of the disease. CK values were not available at 
the time of study.  
Five female individuals (N.03, N.21A, N.27, N.28B, 40C), with an age at last 
assessment ranging from 14 to 68 years, showed raised CK values only or asymmetric 
calf atrophy, while female patients N.02 and N.14, aged 68 and 42 years respectively, 
showed a more pronounced LGMD type weakness. Female patient N.08 (not included 
in table 3 in view of lack of  detailed clinical information) was diagnosed as part of a 
family screening of a previously reported LGMD2L patient. At the age of 44 years 
she does not report any clinical symptoms, but no further clinical information was 
available at time of the study.  
A total of 7 unrelated patients were confirmed with anoctaminopathy, but did 
not carry the common c.191dupA mutation on either allele. Age at onset was 44 years 
on average. Four patients showed a milder phenotype, with a very late onset (77 
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years), normal power or only mild proximal weakness at last assessment. Muscle 
wasting was present in half of them, while upper limb function was normal in all.  
Clinical information were was available for 11/14 unrelated patients with one 
single pathogenic variant (data not shown). Five individuals showed a phenotype 
compatible with a diagnosis of LGMD2L, while 3 subjects only showed raised CK 
values with or without calf hypertrophy. In one individual (Pt N.50) this variant was 
also found in further two family members also affected by isolated hyperCKaemia.  
Clinical analysis of the 7 patients with putatively non pathogenic exonic 
mutations ( Pt. N57-63) showed phenotypes not typical for anoctaminopathy, with 
lower CK values, more severe upper limb involvement or early age at onset (data not 
shown). Phenotypic analysis of patients with intronic changes only (Pt. N 64-90) was 
not performed.  
Discussion 
In this study we report on the clinical analysis and molecular screening of the 
ANO5 gene in the largest cohort of anoctaminopathy patients identified so far. Our 
results confirm the high frequency of the common c.191dupA mutation which 
represents 51/84 (61%) of mutated alleles in the cohort of patients with two mutations 
(Tables 1 and 2). Occurrence of this Northern European founder mutation in patients 
of different geographic origin indicates that it has likely spread worldwide, although 
at lower frequencies compared to the British and German populations. This is 
corroborated by the observation that the mutation has not been observed in 
homozygosity in other populations, with the exception of two unrelated French 
patients (Wahbi et al, 2012). However, our result could have been biased by the 
predominance of British and German patients in our cohort. 
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We identified 34 27 novel variants in the ANO5 gene, 16 135 of which are 
likely pathogenic (Tables 1 and 2). Mutations are spread across the gene, indicating 
the absence of additional mutation hot spots, although some mutations appear to be 
recurrent (Tables 1 and 2). The frequency of the second most common variant 
(c.692G>T) suggests that it could represent an additional common change in our 
population (Table 1). Interestingly, the common Finnish mutation appears to be rare 
in our cohort, with a single occurrence in a German patient in compound 
heterozygosity with the c.191dupA mutation (Pt N.35). Mutations leading to loss of 
protein function (frameshift, splice and stop mutations) were the most common 
changes in the “2-mutation” group of patients (66/84 alleles, 79%) although the 
relative frequency of missense changes (18/84 alleles, 21%) could imply further 
pathogenetic mechanisms.  
We have identified several exonic changes that appear to be benign variants or 
to have uncertain pathogenicity. Among these, the  non pathogenic variant c.155A>G 
(p.Asn52Ser) in exon 4 (dbSNP rs143777403), found with allelic frequency of 
0.0001-0.001 in North American and African American control populations, was 
identified in 5 patients from our cohort. The c.2387C>T (p.Ser796Leu) in exon 22, 
also a benign variant by in silico analysis, was found in another individual. 
Interestingly, these two missense variants were described as pathogenic by Wahbi and 
coauthors (2012) in 3 unrelated subjects, one of which was compound heterozygous 
for this and the c.155A>G variant. These findings point towards caution when novel 
missense changes are found (especially if in compound heterozygosity), and no 
further data corroborating the pathogenicity of the change is available. We identified 
3 patients who were homozygous for a novel variant and 14 patients with 1 
heterozygous change only. One of the limitations of this study is the lack of cDNA 
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studies to exclude 2nd deep intronic changes or gene dosage analysis, but 
deletion/duplication analysis is currently in progress in some of these individuals.  
We have previously described the clinical phenotype of anoctaminopathies as 
an adult onset disease, characterized by slowly progressive muscle weakness mainly 
affecting the pelvic girdle and the lower limbs (Hicks et al, 2011). Clinical analysis of 
the present cohort of patients extends our initial findings to a large group of patients 
not restricted to the common founder mutation (Table 3). Being our center the only 
currently offering ANO5 screening in the UK, the prevalence of proximal disease is 
unlikely to be caused by the referral bias previously suggested (Hicks et al, 2011). No 
major significant cardiac or respiratory disease was observed in this cohort, 
suggesting that these are not major features of the condition. We provide further 
evidence for male predominance in anoctaminopathies, females being overall less 
frequently and less severely affected than males (Hicks et al, 2011, Penttilä et al, 
2012). Phenotypic analysis of the here reported affected females reveals a milder 
clinical picture, with 5 patients showing only raised CK values or calf hypertrophy. 
The oldest female individual, homozygous for the common exon 5 mutation, showed 
a late disease onset (64 years), and at the age of 68 years she was still ambulant and 
she was able to stand on tiptoes and heels with minor difficulties. These findings 
suggest that gender differences could be in part due to the milder phenotype of 
affected females that is therefore less likely to be ascertained. In fact, two 
asymptomatic females were identified after a molecular diagnosis was reached in their 
brothers. Recruitment bias could also be in part be responsible for gender difference, 
as patients seen in specialized centers usually show a more severe phenotype, and 
therefore females with milder phenotypes might not come as frequently to our 
attention. In this study, we also identified 4 male subjects showing a very mild 
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phenotype, ranging from isolated hyperCKaemia to mild proximal leg weakness with 
onset in late adulthood (Table 3). In particular, one subject only showed symptoms in 
his late 70s, confirming that indeed age at onset and severity of anoctaminopathies 
can be extremely variable also in males (Hicks et al, 2010; Schessl et al, 2012; 
Penttilä et al, 2012).  
No genotype-phenotype correlations were noted in anoctaminopathy so far. 
Nevertheless, a clinical comparison between patients carrying the common exon 5 
mutation and those carrying different changes revealed some interesting findings 
(Table 1 and 3). Pattern of muscle involvement and female/male ratio appear similar, 
although the phenotype is somehow milder, with onset at later age in patients carrying 
mutations other than the c.191dupA. Unfortunately the relatively low number of 
patients with different ANO5 changes does not allow any statistically significant 
conclusions. Conversely, phenotypic analysis of heterozygous patients did not 
evidence major differences compared to patients with two mutations, although 3 
heterozygous patients presented raised CK values and mild calf hypertrophy only. 
While we cannot exclude a second non-yet identified change in these subjects, family 
analysis of one individual (Pt. N.50) showed that raised CK values segregated with 
the heterozygous mutation in 2 other family members (data not shown). An 
association between isolated hyperCKaemia and ANO5 heterozygous carrier status 
was suggested by Milone and coworkers, who identified an otherwise asymptomatic 
carrier of the c.191dupA mutation (Milone et al, 2011). Likewise, isolated 
hyperCKaemia or very mild phenotypes were also found in a few male and female 
patients carrying two pathogenic ANO5 mutations (Hicks et al, 2011; Schessl et al, 
2012; Penttilä et al, 2012, Wahbi et al, 2012). Systematic analysis of ANO5 gene in 
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wider cohort of subjects with isolated hyperCKaemia, as well as CK measurements in 
otherwise healthy heterozygous family members could help to clarify these findings.  
Our results show that ANO5 gene mutations are responsible for about ¼ of 
cases of undiagnosed muscular dystrophy with adult onset and raised CK, screened at 
our service over the last two years (present series and Hicks et al, 2011). This value is 
similar to what reported in the Finnish population (Penttilä et al, 2012) and indicates 
anoctaminopathy as one of the most common form of LGMD in our population, 
possible reflection of the founder effects observed in Northern Europe (Hicks et al, 
2011). Indeed, observed incidences in the UK and Finland are higher than in Italy 
(Magri et al, 2012) where only about 2% of undiagnosed LGMD patients were shown 
to carry ANO5 mutations. Based on its relative frequency, screening of the ANO5 
gene now represents an early step in the diagnostic work-up of these patients. 
However, in view of the increasing genetic heterogeneity and prevalence of families 
without the common mutation (14%), analysis should not be limited to founder 
mutations only (Penttilä et al, 2012). More systematic studies on isolated 
hyperCKaemia patients will also help in giving better prevalence data for 
anoctaminopathies in general. 
In conclusion, we confirmed that ANO5 gene mutations are responsible for 
about ¼ of cases of undiagnosed muscular dystrophy in our population, being the 
exon 5 change the most prevalent. We expanded the allelic heterogeneity of the 
disease and recognized a broader clinical spectrum of the disease, ranging from 
isolated hyperCKaemia to full blown LGMD2L, with clear male predominance both 
in terms of overall prevalence and severity of the disease.  
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Table N1. Patients with ANO5 gene mutations  
Patient allele 1 allele 2 Geographic origin 
Patients with 2 pathogenic variants  
N.01-N.16 c.191dupA c.191dupA* Great Britain (12); Germany (4) 
N.17-N22B c.191dupA c.692G>T  Great Britain (7) 
N.23 c.191dupA c.762+1G>A  Great Britain 
N.24 c.191dupA c.1391C>A  USA 
N.25 c.191dupA c.1407+5G>T Belgium 
N.26-N.27 c.191dupA c.1627dupA Spain, n.a. 
N.28A-N.28B c.191dupA c.1643C>T Germany (2) 
N.29 c.191dupA c.1733T>C Great Britain 
N.30-N.32 c.191dupA  c.1898+1G>A Great Britain, Poland and USA 
N.33 c.191dupA c.2395C>T Great Britain 
N.34 c.191dupA  c.2417A>G  USA 
N.35 c.191dupA c.2272C>T Germany 
N.36 c.401A>G c.1898+1G>A Great Britain 
N.37 c.1639C>T  c.1639C>T  n.a. 
N.38 c.2030-1G>T c.2030-1G>T Great Britain 
N.39 
c.2236-13_2236-
4delinsATTCTTCTGGC  
c.2236-13_2236-
4delinsATTCTTCTGGC  
Great Britain 
N.40A-N.40C c.242A>G c.1097A>G Germany (3) 
N.41 c.400C>T c.2235+1G>A France 
N.42 c.989dupTex10 c.2018A>G Great Britain 
Patients with 1 pathogenic variant 
N.43-N.44 c.191dupA c.155A>G Great Britain; n.a. 
N.45-N.47 c.191dupA - Germany (2); Great Britain 
N.48-N.50 c.692G>T - Great Britain (3) 
N.51 c.762+1G>A   c.155A>G USA 
N.52 c.1925G>T  c.1181-21T>A Great Britain 
N.53 c.1640G>A  - Great Britain 
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 2 
N.54 c.2417A>G   - Great Britain 
N.55 c.2521C>G  - Great Britain 
N.56 c.2593A>C  - Pakistan 
Patients with exonic and intronic changes with uncertain pathogenicity 
N.57-N.58 c.155A>G  - Great Britain (2) 
N.59 c.746C>G - Great Britain 
N.60 c.968C>G  - Pakistan 
N.61 c.2256G>A - Great Britain 
N.62 c.2387C>T - Great Britain 
N.63 c.2698A>C. - Germany 
N.64-67 c.364-8dupT c.364-8dupT Africa and Great Britain 
N.68 c.1119+35G>A c.1181-48T>A Germany 
N.69 c.139-59dupT - n.a. 
N.70-78 c.364-8dupT - Africa and Great Britain 
Note: ANO5 gene, Gene Bank accession number NM_213599.2. Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG 
translation initiation codon in the reference sequence, according to journal guidelines (www.hgvs.org/mutnomen). The initiation codon is codon 1. 
Legend: *patient N.05 and N.13 also with variant c.364-67T>C with uncertain pathogenicity. 
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Table 2: List of detected ANO5 gene changes 
Nucleotidic change 
Amino acidic 
change 
Exon 
Intron 
Protein domain Zygosity Reported Interpretation? 
c.139-59dupT   IVS3 CTD 1 HzPt novel  benign in silico 
 c.155A>G p.Asn52Ser 4 CTD 3 CHzPt + 2 HzPt reported  benign in silico 
 c.191dupA    5 CTD 16 HomoZpt+ 19 CHzPt  + 5  HzPt reported frameshift mutation 
c.242A>G   p.Asp81Gly 5 CTD 1 CHzPt reported pathogenic missense change 
c.364-8delT   IVS7 CTD 5 HomoZpt+ 8 HzPt  
novel 
reported 
unconfirmed pathogenicity 
c.364-67T>C   IVS7 CTD 2 HzPt novel  unconfirmed pathogenicity 
 c.400C>T  p.His134Tyr 7 CTD 1 CHzPt novel  pathogenic in silico 
c.401A>G p.His134Arg 7 CTD 1 CHzPt novel  pathogenic in silico 
c.692G>T p.Gly231Val 8 CTD 5 CHzPt+ 3 HzPt reported pathogenic missense change 
c.746C>G  Ala249Gly 8 CTD 1 HzPt novel  benign in silico 
c.762+1G>A   IVS8 CTD 1 CHzPt+1 HzPt novel  putative splice mutation 
c.878+78delT   IVS9 CTD 1 HzPt novel  benign in silico 
c.879-41A>T    IVS9 CTD 1 HzPt novel  unconfirmed pathogenicity 
c.968C>G p.Ala323Gly 10 CTD 1 HzPt novel  unconfirmed pathogenicity 
c.989dupT   10 CTD 1 CHzPt  novel  frameshift mutation 
c.1097A>G p.Asn366Ser  11 ETD 1 1CHzPt 
novel 
reported  
 pathogenic in silico 
 c.1119+35G>A    IVS11 ETD 1 1 CHzPt novel  unconfirmed pathogenicity 
c.1120-24A>T    IVS12 ETD1 2 HzPt novel  unconfirmed pathogenicity 
c.1181-21T>A   IVS13 TMD2 1 HzPt novel  unconfirmed pathogenicity 
c.1181-48T>A    IVS13 TMD2 1 CHzPt +8 HzPt novel  unconfirmed pathogenicity 
 c.1391C>A Ala464Asp 14 TMD3 1 CHzPt novel  pathogenic in silico 
c.1407+5G>T   IVS14 TMD3 1 CHzPt reported  putative splice mutation 
c.1627dupA    15 CTD3 2 CHzPt reported  frameshift mutation 
 c.1639C>T  p.Arg547STOP 16 CTD3 1 HomoZpt novel  stop mutation 
c.1640G>A p.Arg547Gln  16 CTD3 1 HzPt novel  pathogenic in silico 
c.1643C>T pThr548Ile 16 CTD3 1 CHzPt reported  pathogenic in silico 
c.1733T>C Phe578Ser 16 CTD3 1 CHzPt reported pathogenic missense change 
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 c.1898+1G>A    IVS17 ETD3 4 CHzPt reported  putative splice mutation 
c.1925G>T Arg642Leu 18 ETD3 1 HzPt novel  pathogenic in silico 
c.2018A>G Tyr673Cys 18 ETD3 1 CHzPtt reported  pathogenic missense change 
c.2030-1G>T    IVS18   1 HomoZpt novel  putative splice mutation 
c.2235+1G>A   IVS19 TMD7 1 CHzPt novel  putative splice mutation 
c.2236-13_2236-
4delinsATTCTTCTGGC  
  20 TMD7 1 HomoZpt novel  frameshift mutation 
c.2256G>A   20  TMD7 1 HzPt novel  unconfirmed pathogenicity 
c.2272C>T Arg758Cys 20 TMD7 1 CHzPt  reported pathogenic missense change 
c.2387C>T p.Ser796Leu 20  TMD7 1 HzPt reported benign in silico 
c.2395C>T p.Arg799STOP  20   1 CHzPt novel  stop mutation 
 c.2417A>G p.Tyr806Cys 21 ETD4 1 CHzPt+ 1 HzPt novel  pathogenic in silico 
c.2521-13A>G    IVS21 TMD8 1 HzPt 
novel 
reported  
 unconfirmed pathogenicity 
c.2521C>G p.His841Asp  22 TMD8 1 HzPt novel  pathogenic in silico 
c.2593G>T p.Ile865Leu 22 TMD8 1 HzPt novel  pathogenic in silico 
c.2698A>C  p.Met900Leu 22 CTD5 1 HzPt novel   benign in silico 
Note: ANO5 gene, Gene Bank accession number NM_213599.2. Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the 
ATG translation initiation codon in the reference sequence, according to journal guidelines (www.hgvs.org/mutnomen). The initiation codon is codon 1.  
Legend: CTD: cytoplasmic topological domain; ETD: extracellular topological domain; TMD: transmembrane domain; CHzPt: compound heterozygous 
patient, HzPt: heterozygous patient; HomoZpt: homozygous patient; IVS: intron 
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Table 3: Phenotypic analysis of patients with 2 pathogenic ANO5 variants 
Patient 
Age 
(years) 
Sex 
Onset 
CK 
(IU/L) 
Pattern of Muscle involvement at last assessment 
other features 
Age Symptoms  
ambulant  
UL 
prox 
LL 
Prox 
LL 
Distal  
Walk 
on toes 
Walk 
on 
heels 
Muscle atrophy 
scapular 
winging 
AS 
N.01 50 m 38 thigh weakness 241-2603  yes - +++ - diff. diff. thighs - + - 
N.02 68 f 64 proximal LL weakness, thigh wasting n.a. yes +/- +++ - diff diff 
thighs and 
calves (AS) 
- +   
N.03 20 f - - 3300-8800 yes - - - able able - - - - 
N.04 63 m 50s walking difficulties 2122 yes +/- +++ + n.a. n.a. - - - 
calf 
hypertrophy, KH 
N.05 44 m 20s Thigh and calf wasting (AS)  4060 yes - +++ +/- able able 
calves, thighs 
(AS) 
- + 
 Calf 
hypertrophy (as 
child), TA 
contractures, 
ptosis 
N.06 35 m 20s calf swelling, back pain, leg weakness 1642-3080 yes +/- ++ 
++ 
(AS) 
unable unable - - + 
muscle 
twitching, TA 
contractures 
N.07 56 m 40s LL weakness and wasting  1517 yes ++ +++ + unable unable n.a. -     
N.09 40 m 20s 
reduces sport fitness and muscle 
wasting 
4000 yes +/- ++  - able able 
biceps/pectoral. 
quads (AS) 
- +   
N.10 64 m 46 Raised CK and myalgia 2200-3300 yes +/- + - able able quads - - 
Sleep apnoea, 
CTS 
N.11 43 m 20s n.a. 5400 yes no - + diff diff calves (AS) - + 
thigh 
hypertrophy 
N.12 16 m 16 myalgia, raised CK 2000-30,000 yes  +/- - - able able - - - 
neck flexion 
weakness 
N.13 70 m 38 Difficulty running and calf asymmetry 1800 yes +/- 
+ 
(AS) 
+ unable unable 
biceps and 
calves (AS) 
- + 
 Calf hypetrophy 
(AS) 
N.14 42 f 30s prox LL weakness 2500-3000 yes  - + -     vasti +/- n.a.  
calf 
hypertrophy, 
CTS 
N.15 67 m 50s raised CK and myalgia 2100 yes - - - able able - - n.a.  calf hypertrophy 
N.16 44 m 40 Myalgia 1500-2500 yes +/- - - able able - + - 
 
N.17 47 m 20s myalgia 1600-6000 yes - +++ - able unable 
thighs, 
hamstrings 
especially, calf 
(AS) 
- + 
thigh 
hypertrophy, 
CTS 
N.18 65 m 30s walking difficulties 3661 no 60yrs - ++++ - unable unable quads - - calf hypertrophy 
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N.19 40 m 34 LL weakness 5000 yes - +++ +/- able able 
hamstrings, 
buttocks, 
calves 
- -   
N.20 65 m 40s walking difficulties 2000 yes - + - n.a. n.a. n.a.  - n.a.    
N.21A 14 f - - 1200 Yes - - - able able - - - - 
N.21B 17 m - - n.a. - - - - able able - - - - 
N.22A 72 m 50s walking difficulties 900 yes 
+ 
(AS) 
+++ 
(AS) 
n.a.  diff diff + + +   
N.22B 74 m 40s UL weakness 900 yes + 
+ 
(AS) 
n.a.  diff diff 
medial 
gastrocnemius 
(AS)  
+ + 
calf, paraspinal 
muscle 
hypertrophy 
N.23 41 m 38 LL weakness and wasting  209-6301 yes +/- +++ - unable diff 
thighs and 
calves (AS) 
+ (AS) + KH  (AS) 
N.24 55 m 28 weakness in gastrocnemius muscle  2500-4500 yes n.a.  n.a.  n.a.  n.a.  n.a.  n.a.  n.a.  n.a.    
N.25 42 m 23 Wasting and weakness left calf 5300-12500 yes - - ++ unable able calves - + 
 
N.27 41 f 34 hyperCKaemia 2503 yes - - - able able 
gastrocnemius 
medialis (AS) 
- +   
N.28A 56 m 40 asymmetric thigh weakness 1500-6100 yes +/- ++ - diff diff. Thighs (AS) - +   
N.28B 53 f - - 2280 yes - - - able able - - -   
N.29 64 m 30s  difficulties with climbing stairs 829 yes +/- +++ +++ unable unable   - + 
calf hypertrophy 
(AS), IHD 
Anaemia, FVC 
70% 
N.30 61 m 30 weakness in LL muscles 5956 yes n.a.  n.a.  n.a.  n.a.  n.a.  n.a.  n.a.  n.a.    
N.31 28 m 20 difficulties running 7868 yes - 
+++ 
(AS) 
- able able 
UL, 
bamstrings, 
buttocks, quads  
- + 
sensory axonal 
polyneuropathy 
N.32 52 m 20s hyperCKaemia and calf wasting >3000 yes 
+/- 
(AS) 
+++ - unable able 
vastus 
medialis, calf 
(AS)  
+/- + TA contractures  
N.33 32 m 20s LGMD type weakness  n.a. restricted - +/- + n.a.  n.a.  
biceps, medial 
quads, calf 
(AS) 
n.a.  +   
N.34 32 m 22 calf wasting, unable to stand on toes 10,000 yes n.a.  n.a.  n.a.  n.a.  n.a.  n.a.  n.a.  n.a.    
N.35 29 m 23 Calf muscles stiffness when walking 1700-2900 yes - - +/- diff 
unable 
(AS) 
calves (AS) - +   
N.36 54 m 32 proximal LL weakness 4029 yes - +/- - able able - - -   
N.38 77 m 77 proximal LL weakness and raised CK 4400 yes n.a. 
+ 
(AS) 
- able able LL (AS) - +   
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N.39 59 m 38 left LL weakness 3000 yes - +/-   unable unable thighs (AS) - + 
hypertension, 
KH (AS) 
N.40A 32 m 21 
decreased endurance, inability standing 
on right   tiptoes and raised CK  
4200-22.000 yes - ++ + unable able 
adductors, 
quadriceps and 
calves 
- + KH 
N.40B 13 m - - 1970 yes - - - able able - - -   
N.40C 23 f 21 myalgia 861 yes - - - able able - - -   
N.41 56 m 35 difficulties running 1168-3612 yes - ++ ++ unable able 
thighs and 
calves 
- -   
N.42 44 m 39 distal weakness and calf wasting 2666- 4200 yes - + ++ unable able 
UL (distally),  
thighs, calves 
- - 
hand weakness, 
back twitching   
Legend: Pt, patient number; CK, creatine kinase; UL, upper limbs; LL, lower limbs; AS, asymmetry; m, male patient; f,  female patient; diff, able with 
difficulties; n.a, data not available; TA, Achilles tendons; KH, knee hyperextension; IHD, ischaemic heart disease; FVC, forced vital capacity; CTS: carpal 
tunnel syndrome; +, ++, +++: grade of weakness (from milder to more severe)  
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Table S1. Patients with ANO5 gene mutations  
Patient allele 1 allele 2 Geographic origin 
Patients with exonic and intronic changes with uncertain pathogenicity 
N.57-N.58 c.155A>G  - Great Britain (2) 
N.59 c.746C>G - Great Britain 
N.60 c.968C>G  - Pakistan 
N.61 c.2256G>A - Great Britain 
N.62 c.2387C>T - Great Britain 
N.63 c.2698A>C. - Germany 
N.64-67 c.364-8dupT c.364-8dupT Africa (2) and Great Britain (2) 
N.68 c.1119+35G>A c.1181-48T>A Germany 
N.69 c.139-59dupT - n.a. 
N.70-78 c.364-8dupT - Africa (1) and Great Britain (8) 
Legend: ANO5 gene, Gene Bank accession number NM_213599.2. Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the 
ATG translation initiation codon in the reference sequence, according to journal guidelines (www.hgvs.org/mutnomen). The initiation codon is codon 1.  
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